CDSCO rolls out prior intimation system to fast-track drug testing and R&D

Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development

MSN Laboratories launches SEMABEST, India-made semaglutide pen at nearly 50% lower price

CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing

CDSCO invites bids for next-gen Digital Drugs Regulatory System

API-first, DPI-driven DDRS platform aims to modernize drug and medical device regulation in India

IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals

AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17

NATCO launches Semaglutide generic injection multi dose vials in India at affordable price of Rs. 1,290

Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India

The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape

NATCO receives CDSCO approval for Semaglutide in India

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus

Budget 2026-27: Government launches Rs. 10,000 crore Biopharma SHAKTI Scheme to build global manufacturing hub

A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave

Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare

The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education